Skip to main content Skip to section navigation Skip to footer
Avalo Therapeutics, Inc. IR Overview
  • Overview
  • News, events & presentations
    • Press Releases
    • Events
    • Presentations
    • Email alerts
  • Analyst coverage
  • Stock data
    • Quote and chart
    • Historical data
  • SEC filings
    • SEC filings overview
    • All SEC filings
    • Annual reports
    • Quarterly reports
    • Section 16 filings
  • Corporate governance
    • Board Committees & Governance Documents
    • Board of directors
  • IR resources
    • Contacts
    • FAQ
Avalo Therapeutics, Inc. Corporate Home
  • About
    • Overview
    • Leadership
    • Board of directors
    • Contact
  • Science
    • Overview
    • IL-1β in HS
    • IL-1β in CPPD
  • Pipeline
    • Overview
    • AVTX-009 for HS
    • AVTX-009 for CPPD
  • Patients
    • Our commitment
    • Clinical trials
    • Resources
    • Access to investigational therapies
  • Investors
    • Overview
    • News, events & presentations
    • Analyst coverage
    • Stock data
    • SEC filings
    • Corporate governance
    • IR resources
  • Careers
    • Overview
    • Values
    • Benefits
    • Job openings

Press Releases

News, events & presentations

News, events & presentations

  • Press Releases
  • Events
  • Presentations
  • Email alerts
Sep 14, 2021 4:01 pm EDT
Avalo Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
Aug 26, 2021 7:30 am EDT
Avalo Therapeutics, Inc. Announces Corporate Name Change from Cerecor Inc.
Aug 2, 2021 4:01 pm EDT
Cerecor Reports Second Quarter 2021 Financial Results and Provides Business Updates
Aug 2, 2021 7:30 am EDT
Cerecor Announces Drawdown of $10 Million Tranche under its Debt Financing Agreement with Horizon Technology Finance
Jul 26, 2021 4:01 pm EDT
Cerecor Announces Positive Initial Phase 1b Results for CERC-002 in Moderate to Severe Crohn's Disease Patients
Jun 23, 2021 7:30 am EDT
Cerecor Licenses Immune Checkpoint Program from Sanford Burnham Prebys Further Expanding Pipeline of Immunology and Immuno-oncology Targets
Jun 7, 2021 7:00 am EDT
Cerecor Enters Into $35 Million Debt Financing Agreement With Horizon Technology Finance
May 17, 2021 7:00 am EDT
Cerecor to Participate in Upcoming Investor Conferences
May 13, 2021 7:00 am EDT
Cerecor Reports First Quarter 2021 Financial Results and Provides Business Updates
May 11, 2021 7:00 am EDT
FDA Grants Fast Track Designation to CERC-002 for Treatment of Hospitalized Patients with COVID-19
  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • Page 11
  • Page 12
  • …
  • Page 21
  • Next Pagearrow_forward
  • Contact IR
  • RSS
  • Email Alerts
  • Accessibility
    accessibility
410.522.8707
in
1500 Liberty Ridge Drive
Suite 321
Wayne, PA 19087
Avalo
PRIVACY POLICY DISCLAIMER
©2025 Avalo Therapeutics, Inc.